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a b s t r a c t
This review highlights recent advances in atopic dermatitis (AD) and food allergy (FA), particularly on
molecular mechanisms and disease endotypes, recent developments in global strategies for the man-
agement of patients, pipeline for future treatments, primary and secondary prevention and psychosocial
aspects. During the recent years, there has been major advances in personalized/precision medicine
linked to better understanding of disease pathophysiology and precision treatment options of AD. A
greater understanding of the molecular and cellular mechanisms of AD through substantial progress in
epidemiology, genetics, skin immunology and psychological aspects resulted in advancements in the
precision management of AD. However, the implementation of precision medicine in the management of
AD still requires the validation of reliable biomarkers, which will provide more tailored management,
starting from prevention strategies towards targeted therapies for more severe diseases. Cutaneous
exposure to food via defective barriers is an important route of sensitization to food allergens. Studies on
the role of the skin barrier genes demonstrated their association with the development of IgE-mediated
FA, and suggest novel prevention and treatment strategies for type 2 diseases in general because of their
link to barrier defects not only in AD and FA, but also in asthma, chronic rhinosinusitis, allergic rhinitis
and inﬂammatory bowel disease. The development of more accurate diagnostic tools, biomarkers for
early prediction, and innovative solutions require a better understanding of molecular mechanisms and
the pathophysiology of FA. Based on these developments, this review provides an overview of novel
developments and advances in AD and FA, which are reported particularly during the last two years.
Copyright © 2019, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
There are remarkable recent developments understanding the
mechanisms, diagnostic and therapeutic management of atopic
dermatitis (AD) and food allergy (FA) and differences in the practice
by dermatologists and pediatricians in different countries. AD is a
chronic inﬂammatory pruritic skin disease that affects a large
number of children and adults in industrialized countries. Its
worldwide prevalence, ranges from 0.2% to 24.6%, with the highest
prevalence of AD in childhood in Africa and Latin America.1 The
onset of AD occurs during the ﬁrst year of life in 60% of the chil-
dren.2 The prevalence of AD in the ﬁrst 2 years of life is 21.5%.3 43.2%
of these children have spontaneous outgrow of the disease, 38.3%
persist withmild AD andmild rhinitis and 18.7% persist with severe
disease and show an extensive atopic march including FA, asthma,
and rhinitis.3 Only 16.8% of AD patients have onset after adoles-
cence.4 AD and FA are extensively overlapping. The prevalence of FA
has been suggested to increase in the last two decades and is in the
range of 4% in food challenge tests in 1 year, which increases to
6e8% in questionnaire surveys.5 FA shows various different clinical
presentations with respect to responsible allergens, age at pre-
sentation, timing of reaction, presence of comorbid atopic diseases,
outgrow and resolution with time, and response to immuno-
therapy. This heterogeneity of clinical presentations of FA possess a
challenge to successful management and treatment. Avoidance of
allergenic foods and the use of epinephrine in case of a severe re-
action triggered by accidental ingestion remain the standard of
care, as there are currently no approved treatments for FA. Dysre-
gulated immune response patterns and their heterogenous and
complex combination in chronic inﬂammation, immune cell and
tissue cell hyperresponsiveness, microinﬂammation even at the
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healing stage and tissue remodeling in affected tissues deﬁne the
complexity of FA and AD.
Modern healthcare is rapidly developing and staying away from
the concept of including all of the patients in one basket to an
individualized response with the combination of precision diag-
nosis and personalized treatment. An overarching medicinal
concept is developing with better understanding of genotypes,
phenotypes, endotypes, regiotypes, biomarkers and theratypes of
diseases that also fully include AD and FA.6 More than 100 years old
allergen-speciﬁc management of allergic diseases has particularly
contributed to the early awareness in precision medicine. Multi-
pleomics, big data, and systems biology have demonstrated a pro-
found complexity and dynamic variability in AD and FA between
individuals, as well as between regions.6
Basic research has intensiﬁed during the recent years to better
understand the immune and inﬂammatory mechanisms in AD and
FA. IgE sensitization, essential molecular pathways of type 2
response, mechanisms of disease outgrow and therapy response
are important in both diseases. Mechanisms of desensitization,
successful ways of treatment without side effects and short- and
long-term tolerance mechanisms are key research areas in FA. This
article highlights and summarizes key advances in AD and FA
published during the last couple of years. Important ones from
these achievements are summarized in Tables 1 and 2.
Global strategies for the assessment and management of
atopic dermatitis
There is a consistent association of AD with other atopic diseases
including asthma and FA. The concept of atopicmarchwas developed
to describe the progression of these atopic diseases in children.7
Although it most often starts in infancy, it is also highly prevalent in
adults.8 Among the adult AD population, a multidimensional burden
has been described not only including dermatologic symptoms, but
also increased socioeconomic burden, sleep disorders, and reductions
in health-related quality of life and work productivity.9e11 With
increasing severity, the multidimensional burdens listed above also
increase. International Classiﬁcation of Diseases, 11th Revision (ICD-
11) was provided,12 and ICD-9, clinical modiﬁcation codes alonewere
found to be insufﬁcient for identiﬁcation of AD from healthcare da-
tabases, but incorporation of the diagnosis of asthma, hay fever, and
FA improved the positive predictive value and speciﬁcity of these
searches.13 TheHarmonizingOutcomesMeasures for Eczema (HOME)
initiative is an evidence driven and evidence-generating outcomes
research initiative that aims to develop standardization of a core set of
outcomemeasurements of atopic eczema, which is also known as AD
or eczema.14,15 Various instruments exist tomeasure symptoms in AD
to assess safetyandefﬁcacyof therapies in clinical trials.16,17 Among18
instruments, the pediatric Itch Severity Scale (ISS), Patient-Oriented
Eczema Measure (POEM), Patient-Oriented SCOring Atopic Derma-
titis (PO-SCORAD), Self-Administered EczemaArea and Severity Index
(SA-EASI), and adapted SA-EASI are currently recommended for
assessing symptoms of AD in future clinical trials.18 However, the use
of simple patient-reported global AD severity scores is feasible for
clinical practice and epidemiological research. A simple scoring sys-
tem of mild, moderate, and severe patient-reported AD severity
correlated well with objective AD assessments, objective SCORAD,
and EASI.19 Patient-reported AD severity may be sufﬁciently valid for
assessing AD severity. For the management of AD, patient's increased
adherence to topicalmedication is indispensableparticularlywith use
of topical corticosteroids. The topical corticosteroid phobia (TOPICOP)
score is available for the assessment of topical corticosteroid phobia
based on 12 items.20 TOPICOP scorings can feasibly be applied inter-
nationally and can be used to obtain data from studies and to adapt
patient education and treatment.21
The lifetime prevalence of atopic diseases is signiﬁcantly
increasing from adolescence to adulthood, particularly that of
allergic rhinitis.22 Regarding the clinical course of AD, no signiﬁcant
difference in AD prevalence before and after childhood has been
found by systemic review and meta-analysis of longitudinal
Table 1
Key developments and advances in atopic dermatitis (AD).
Developments and Advances References
Global strategies for the assessment and management of AD
Validation of International Classiﬁcation of Disease Hsu et al.13
Evaluation of symptom measurement instruments Blauvelt et al.17, Vakharia et al.19, Stalder et al.21
Lifetime prevalence Mortz et al.22, Abuabara et al.23, Barbarot et al.24
Product-speciﬁc standardization Zimmer et al.26, Bonertz et al.28
Prevention of AD
Atopic march Han et al.29, Ferreira et al.31
Microbiome and immune system Chu et al.35
Prevention approach to decrease AD Elbert et al.38, Roduit et al.41, Silverwood et al.43
Psychological aspects of AD
Management of psychological status Ronnstad et al.48
Attention-deﬁcit/hyperactivity disorder Schmitt et al.53
Mechanisms and pathophysiology of AD
microRNA and AD Carreras-Badosa et al.60
Periostin and epidermal barrier Mitamura et al.61, Izuhara et al.62
Biomarker Czarnowicki et al.65
T-cell receptor repertoire Brunner et al.66
Mast cells and sphingosine-1-phosphate activation Wedman et al.69
Langerhans and inﬂammatory dendritic epidermal cells Otsuka et al.72
Aryl hydrocarbon receptor mediated anti-inﬂammatory feed back Koch et al.75
Therapeutic targets and experimental models for the treatment of AD
Allergen speciﬁc immunotherapy Shin et al.131
Oral tolerance Baek et al.77
Topical ivermectin Ventre et al.79
Mesenchymal stem cells Song et al.80
Antimicrobial peptide Kopfnagel et al.83
Chemokine receptors Murray et al.85
BCG vaccination Thostesen et al.87
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studies.23 In studies of AD prevalence by country, estimations of
adult AD prevalence ranges from 2.1% to 4.9%.24 For international
clinical and epidemiological research, it is becoming increasingly
clear that differing nomenclature of the disease has important
harmful or unwanted consequences.25 AD as well as the term atopic
eczema describe clinically chronic relapsing pruritic inﬂammatory
skin conditions. In this context, the International Eczema Council
(IEC) noted that the term eczema is imprecise and confusing and
recommended the use of AD or atopic eczema in all publications,
presentations and discussions about the disorder.25
Product-speciﬁc standardization is of critical importance for pa-
tients with suspected or proven allergy.26 Ensuring persistent quality,
safety, and efﬁcacy of medical allergen products is required for an
effective treatment. Products for allergen immunotherapy (AIT) have
been approved by national authorities; however, different regulations
exist worldwide. Although regulatory framework in the European
Union (EU) has been developed in the ﬁeld of AIT, it remains het-
erogeneous. New allergen products for AIT are being developed and
manufactured each year. However, despite the increased number of
medical products such as AIT, regulatory framework for quality pa-
rameters has not yet been reached. Thus, it is extremely complicated
and challenging to develop a harmonized international approach to
regulation. International pharmaceutical companies have recently
placed an emphasis on medical products that promote health and
supply local and neighboring markets as well as global markets.
Therefore, it is quite important to understand the regulation of
allergen products from a global perspective. From these kind of cir-
cumstances, the EAACI Taskforce on Regulatory Aspects of Allergen
Immunotherapy, as a part of the EAACI AIT Guidelines, analyzed how
products for the diagnosis of allergies and AIT are regulated in
different countries and regions worldwide.27 They also provided an
overview of how AIT products are regulated with respect to their
manufacturing and quality in EU, and United States.28 They described
similarities and differences in the regulation of allergen
manufacturing and quality control between the EU andUnited States.
Prevention of atopic dermatitis
The development of AD in infancy and subsequent conditions
such as FA, asthma, and allergic rhinitis has been observed as co-
manifestation or occurring in sequence. These longitudinal
associations have been known to lead to atopic march,29 and an
association between AD and birch pollen allergy has also been re-
ported.30 There has been controversy regarding whether atopic
march is the primary causal factor in childhood allergic diseases. A
recent study indicated that AD, asthma and allergic rhinitis partly
coexist, because they share many genetic risk variants that dysre-
gulate the expression of immune-related genes.31 Another study
showed that the risk of developing asthma or allergic rhinitis was
much higher in IgE-associated AD compared to nonallergic AD.32
Therefore, it has been argued that it is important to distinguish
between eczema with and without IgE sensitization when consid-
ering the implications of allergic diseases in infancy.32,33
Environmental factors, such as bacteria inﬂuence the human
microbiome and immune system. Development of novel preventa-
tive approaches is important, and a recent review summarizes cur-
rentevidence for thepotential of bacteria and theirmetabolites in the
prevention of allergic diseases.34 Early life microbial exposure in-
ﬂuences the risk of allergies and development of a balanced immune
system.35,36 Not only the exposure, but also the correct composition
of the gut microbiota have a role in allergy development.37
Furthermore, the increased incidence of AD and the progression
from AD to allergic rhinitis and asthma have highlighted the need
for disease prevention. A recent article indicates that shorter
duration or non-exclusive breastfeeding was associated with a
weak overall increased risk of AD, but not sensitization.38 Con-
cerning the inﬂuence of pregnancy-related and perinatal factors,
children who are born by cesarean section and assisted-delivery
showed signiﬁcant associations with AD, asthma and atopic
sensitization in childhood.39 Effect of food diversity in childhood
has also been investigated. The consumption of cheese had a sig-
niﬁcant protective effect for AD.40 The effect on AD may be asso-
ciated with the diversity of consumed cheese, including those rich
in microbial diversity. It has to be noted here that cheese is an
important provider of short chain fatty acids that are linked to
prevention of AD in children and mouse models.41 Despite a pre-
ventative approach to decrease AD in early-childhood, some pa-
tients may have persistent disease into adulthood. However, the
prevalence of comorbidities in patients with AD is not well char-
acterized.42 Recent studies have shown that patients with severe
AD had a high prevalence of smoking, stroke, cardiovascular dis-
ease, inﬂammatory bowel disease, depression and anxiety.42,43
Table 2
Key developments and advances in food allergy (FA).
Developments and Advances References
Diagnosis and the role of biomarkers in early prediction
Precision medicine in FA Agache et al.6, Flores et al.97
Assessing basophil activation Mukai et al.95
Prediction of FA Datema et al.100, Pettersson et al.109, Baumert et al.111
Predictive biomarkers of anaphylaxis Turner et al.112
Innovative solutions
Allergen exposure chambers Rosner-Friese et al.124, Pfaar et al.126
Companion animal research Jensen-Jarolim et al.134
Mechanisms and pathophysiology
Vitamin D and mast cell stabilization Liu et al.145
Epigenetic mechanisms Asai et al.150
Intestinal microbiome and food sensitization Savage et al.149
microRNA and FA D'Argenio et al.153
Tolerance development Sampson et al.147
Characterization of the T-cell response Zulehner et al.164
Novel strategies for the treatment and management
Allergen immunotherapy Burks et al.166, Wood171, Ryan et al.174
Patient's quality of life Rigbi et al.168
Nanoparticles for allergen-speciﬁc immunotherapy Pohlit et al.176
Combination therapy MacGinnitie et al.173
Early peanut and egg introduction Greenhawt et al.180, Shaker et al.182
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These comorbidities might represent targets for prevention and
intervention of AD management.
Psychological aspects of atopic dermatitis
AD has been thought to carry an increased risk for mental dis-
orders.8 However, few studies have reported the prevalence of
psychiatric disorders among adults with AD. A recent study
revealed that adolescents with AD from Korea are associated with a
higher prevalence of depression symptoms and suicidal behav-
iors.44 A poor health-related quality of life is linked with depressive
mood, depression, and suicidal ideation, which are, in turn, asso-
ciated with AD.45 Therefore, improving poor health-related quality
of life and managing psychological status in AD among adolescents
are critical. From a population-based survey using large-scale
observational data, association among depression, anxiety, and
AD has been analyzed.46 The risk of hospitalization and suicide was
also examined. They found a signiﬁcant association between self-
reported AD among adults and clinician-diagnosed psychiatric
status, including depression and anxiety.46 Moreover, a recent
study of the association between AD and suicidality suggests that
patients with AD are at an increased risk of suicidal ideation and
suicide attempts.47 However, depression, anxiety, and suicidal
ideation do not lead to psychiatric consultations, hospitalization, or
suicide.46 One study reported that improvement of AD appears to
be reduced these psychiatric conditions.48
Epidemiological studies using standardized diagnostic criteria
suggest that 3%e6% of the child population may suffer from
attention-deﬁcit/hyperactivity disorder (ADHD) and more recently,
a relevant association between AD and ADHD has been re-
ported.49,50 Moreover, children with ADHD are more likely to have
not only AD but asthma, allergic rhinitis, and allergic conjunctivitis
than their counterparts.51 A Swedish birth cohort study found that
preschool eczema was not associated with ADHD medication at
school age.52 To shed more light on the comorbidity of AD and
ADHD, Schmitt et al. hypothesized that children with AD, who do
not meet the complete diagnostic criteria of AD frequently show
features of ADHD and increased mental health problems.53 They
concluded that even if the clinical diagnosis of ADHD is excluded,
children with AD show increased levels of ADHD symptoms.53
Despite these ﬁndings, the underlying biological mechanisms still
require further investigation. Therefore, prevention and effective
treatment of AD represent unmet needs in children as well.
Mechanisms and pathophysiology of atopic dermatitis
Major mechanisms of AD include abnormalities in the terminal
differentiation of keratinocytes that lead to a defective stratum
corneum.54,55 A defective barrier in AD allows the penetration of
allergens and microbes, leading to IgE sensitization and type 2
cytokine production that drives allergic inﬂammation.56 At least
two AD subtypes can be distinguished: the ﬁrst type is character-
ized by a strong type 2mediated responsewith high levels of serum
immunoglobulin E (IgE) and the second is a nonallergic type
characterized with normal IgE levels.8,57 MicroRNAs (miRNAs) are
short, single-stranded RNA molecules that regulate Th2 skewing
and inﬂuence innate and adaptive immune responses.58,59 Among
miRNAs, miRNA-146a is needed for the production of IgE and
linked to the modulation of Th1/Th17 cell mediated responses in
mice.60 A matricellular protein, periostin, is induced by Th2 cyto-
kines IL-4 or IL-13 and plays an important role in barrier dysfunc-
tion. A recent study shows that IL-24, produced in keratinocytes
downstream of periostin and IL-13, decrease ﬁlaggrin expression
that leads to barrier dysfunction in AD.61,62 In AD, Th2 cells as well
as other T-cell subpopulations (Th1, Th17, and Th22) are detectable
in the AD skin lesions. Figure 1 shows immune and inﬂammatory
cells in AD. It is important to emphasize that the majority of T cells
in AD skin lesions are cutaneous lymphocyte-associated antigen
(CLAþ)CD45ROþ memory T cells.63,64 Due to recirculation, periph-
eral CLAþT cells have similar features characteristic of T cells pre-
sent in AD skin lesions.65 Various skin T cells, such as CD4 TH1 cells,
CD4 TH2, CD4 TH17, CD4 TH22, CD4 Treg, resident memory T cells,
gd T cells, CD8 TC1, CD8 TC2, Mucosal-associated invariant T cells
(MAIT) are described in Table 3. One recent advancement in ADwas
evidence showing that circulating CLAþ T cells can be a reliable
peripheral biomarker of inﬂammatory events occurring in the
skin.65 There is conﬂicting literature regarding the diversity of T-
cell receptor (TCR) repertoire in AD skin lesions and their rela-
tionship to nonlesional skin. In this context, Brunner et al. showed
that nonlesional AD skin shares a TCR repertoire similar to lesional
AD skin.66
Other cell types, such as innate lymphoid cells (ILC), mast cells,
eosinophils, basophils, and inﬂammatory dendritic cell populations
can be detected in AD skin.67 In human skin mast cells, proteomic
analysis identiﬁes two novel mast cell proteins, L1CAM/CD171 and
DPP4/CD26, that are potentially relevant to skin homeostasis.68
Skin mast cell and sphingosine-1-phosphate (S1P) activation is a
novel effector that initiates remodeling in AD.69 Several ILC-
modulating factors are dysregulated in AD and the levels of IL-25,
IL-33, TSLP, and PGD2 are elevated in AD skin.70 In addition,
cellecell interactions between ILC2s and keratinocytes lead to
activation or suppression of ILC2s.70 Identiﬁcation of surface mol-
ecules on these cells involved in type 2 immunity could provide
new therapeutic targets for the treatment of AD. Blom et al. iden-
tiﬁed, for the ﬁrst time, the expression of CD200R by cells such as
ILC2, Th2, and basophils. Interleukin-31 (IL-31), preferentially
produced from Th2 cells, binds to the IL-31 receptor (IL-31R)
expressed on sensory nerves. IL-31/IL31R signaling has recently
been shown to play a critical role in the development of pruritus in
AD.71 In the skin, there exists at least three populations of antigen-
presenting cells including Langerhans cells (LCs), monocyte-
derived LC-like cells, and inﬂammatory dendritic epidermal cells
(IDECs).72 IDECs and LC-like cells have been found to be present in
both steady states and inﬂammatory states, and they are present in
AD.73 LC and IDEC in AD skin do not respond to Toll-like receptor
(TLR) 2 activation and may contribute to the inability to clear
S. aureus infection.74 LC in patients with AD carry the high-afﬁnity
receptor for IgE, FcεRI, and are engaged in the pathogenesis of AD.
The aryl hydrocarbon receptor mediates the anti-inﬂammatory
feedback mechanism in FcεRI-expressing human LC.75
Future therapeutic targets and experimental models for the
treatment of atopic dermatitis
Although there are many available treatments for allergic dis-
eases, AIT induces establishment of long-term clinical tolerance to
allergens, resulting in the prevention of further development of
allergic diseases and a role for primary prevention has also been
suggested.76 Among currently investigated AIT routes in FA, oral
immunotherapy (OIT) involves the oral administration of
increasing amounts of allergens.76 The transcriptomic proﬁles of
skin obtained from mice that were epicutaneously sensitized, but
orally tolerized indicate that oral antigen administration provides
protection against AD by the expression of genes regulating Th2
inﬂammatory responses and skin barrier function.77,78 In a relevant
mouse model of AD, another study reported the efﬁcacy of topical
ivermectin, a drug used for scabies and rosacea, improved AD by
inhibiting the priming and activation of allergen-speciﬁc T cells.79
Several recent studies have shown promising results in the use of
mesenchymal stem cells for the treatment of AD.80,81 Sah et al.
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explored the clinical potential for superoxide dismutase 3-
transduced mesenchymal stem cells in mice with AD. They
showed that subcutaneously administrated superoxide dismutase
3-transduced mesenchymal stem cells suppress skin inﬂammation
via the histamine H4 receptor/IL-4 receptor-dependent mecha-
nism.81 Succinate is an intermediate of the citric acid cycle that
binds to its speciﬁc receptor, SUCNR1/GPR91. In addition, it acts as
an alarmin and is involved in tissue injury or inﬂammatory stim-
ulus. Furthermore, GPR91, a metabolic control receptor for the
binding of succinate, deﬁciency in mice leads to allergic contact
dermatitis, suggesting that GPR91 is a therapeutic target for the
treatment of allergic skin diseases.82
In humans, Kopfnagel et al. investigated the effect of RNAse 7, a
14.5-kDa antimicrobial ribonuclease on isolated humanTcells.83 They
demonstrated that CD4þ T cells from AD patients showed a less
pronounced downregulation of IL-13 in response to RNAse 7
compared to healthy controls.83 Thus, RNase 7 has immunoregulatory
functions on Th2 cells and reduces the production of Th2 cytokines in
the skin.
Many receptors have been studied, such as CCR4, CCR10, and
CCR8, for the recruitment of immune cells to the skin.84e86 Due to
the complexity of AD, it would be interesting to target speciﬁc cells
with cocktails of chemokine receptor antagonists administered as
ointments on the skin.84 In a randomized clinical trial of neonatal
Fig. 1. T cells and dendritic cells in atopic dermatitis. T cells in uninvolved skin, early lesions and chronic lesions of type 2 AD. T cells are moderately increased in the dermis in the
dermis of non-lesional skin. Skin homing CLA þ T cells display a Th2 proﬁle in early lesions and in the circulation. However, in the course of the disease, increasing populations of
Th1 cells and IFN-g and sometimes Th17 and Th22 cells are detected in chronic lesions of AD. IL-33, IL-25 and TSLP released from keratinocytes directly or indirectly support the
type 2 response. IL31 released from T cells plays a major role in itch. Three populations of antigen-presenting cells including Langerhans cells (LCs) monocyte-derived LC-like cells,
and inﬂammatory dendritic epidermal cells (IDECs) exist in the skin. IDECs and LC-like cells have been found to be present in both steady states and inﬂammatory states, and they
are present in lesional AD.
Table 3
T cell subsets in the skin.
Different conventional and non-conventional T cells Major functions
CD4 TH1 AD chronic lesions, ACD, drug exanthemas, mechanisms of eczema formation
CD4 TH2 AD lesions, AD and general allergy allergen-speciﬁc Th2, eosinophilic skin disease
CD4 TH17 AD chronic lesions, psoriasis, neutrophilic drug exanthemas
CD4 TH22 AD late lesions
CD4 Treg Controls overactivation of other subsets in peripheral blood and lymphatic organs in AD, ACD.
Does not exist too many in lesional skin
TRM Resident memory T cells, mainly against infectious agents, mostly CD8
gd T cells Against infectious agents in mice, very few in human skin
CD8 TC1 Against viruses and other infectious agents, found in AD and ACD skin and drug exanthemas
CD8 TC2 AD, eosinophilic skin diseases
MAIT cells Mucosal-associated invariant T cells, against bacteria and fungi, riboﬂavin responsive and
MR-1 tetramer responsive
AD, atopic dermatitis; ACD, allergic contact dermatitis.
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BCG vaccination in the Danish population, BCG vaccination at birth
was found to be associatedwith less AD among childrenwith atopic
predisposition, although more studies are needed to conﬁrm these
ﬁndings.87
Precision medicine for food allergy: diagnosis and the role of
biomarkers in early prediction
Molecular mechanism-linked therapies can be deﬁned as ther-
apies tailored to the characteristics of each patient to obtain a better
clinical outcome. These different therapeutic responses linked to
individual patient's biological mechanisms is known as precision
medicine.88 Precision medicine consists of four main components
including disease taxonomy, digital monitoring of patients and
biomarkers, disease phenotypes and endotypes, and biomarker-
and endotype-linked patient care and therapies.89 Three main pil-
lars of precision medicine are endotypes, phenotypes, and bio-
markers.89 Important concepts such as regiotypes and theratypes
have been recently introduced. Both regiotypes (regional differ-
ences in pheno and endotypes as well as allergens affecting
different parts of the world) and theratypes (treatment response)
represent important advancements for precision diagnosis and
treatment.6 Of all allergic diseases, FA is particularly well-suited as
a target for precision medicine. This is due to its pathophysiology,
the modulation of which has resulted in better clinical outcomes,
and additionally has been clearly associated with detectable bio-
markers90,91 The consensus document of EAACI and American
Academy of Allergy, Asthma and Immunology (AAAAI) has been
recently published under the auspices of the PRACTALL collabora-
tion platform.92 PRACTALL is an initiative of EAACI and AAAAI to
harmonize the European and American approach to allergic dis-
eases with regard to patient treatment and scientiﬁc progress.90 In
the consensus document, special consideration was given to
deﬁning endotypes in order to assist in developing novel thera-
peutic approaches. The deﬁnition of endotypes in FA is necessary to
develop novel therapeutic approaches. FA endotypes can be char-
acterized into IgE-mediated endotypes, including alpha-gal allergy
and oral allergy syndrome, and non-IgE-related and mixed endo-
types such as food protein-induced gastrointestinal endotype and
eosinophilic endotype.93,94 Diagnostic tools and biomarkers for
accurate diagnosis, evaluation of prognosis, and efﬁcacy of treat-
ment are still under investigation, but basophil activation test and
component-resolved diagnostics are promising tools.95,96 A recent
systematic review showed that selected components of cow's milk,
hen's egg, peanut, hazelnut, and shrimp allergen revealed high
speciﬁcity for diagnosis of FA in component resolved diagnosis.97,98
In a multicenter study, the detection of Ana o 3-speciﬁc IgE pro-
vides a predictive value in the diagnosis in children with suspected
cashew allergy.99 A combination of component-resolved di-
agnostics and other factors such as clinical background and extract-
based serology has been proposed to predict severe reactions to
hazelnut allergy.100 Several biomarkers have been associated with
FA including skin prick tests, allergen speciﬁc IgE, IgG4, genetic, and
epigenetic markers.92,101e104 A study of patients with meat allergy
revealed that the IgG subclass distribution in these patients is
distinct from natural IgG responses in nonallergic individuals.105
Due to a frequent co-sensitization to birch pollen allergens and
proﬁlins, diagnosis of lipid transfer proteins (LTPs) using plant ex-
tracts is difﬁcult.106 In a study from a central European population,
Pru p 3, peach LTP, can be used as an allergen marker for LTP
sensitization.107 To identify diagnostic markers for anaphylaxis in
food allergic patients, Wittenberg et al. found serum levels of
apolipoproteins as a useful biomarker of anaphylaxis.108
Early prediction of the severity of FA is one of the key issues for
the accurate diagnosis and improved management. The extent to
which the severity of food allergic reactions can be predicted by
clinical factors such as age, type of food, and eliciting dose is
currently unknown.109 Several studies provided evidence that the
eliciting dose contributes to the frequency of accidental re-
actions.110,111 Another study suggests that individuals have a
threshold of reactivity for symptoms in general as well as a
threshold for symptoms speciﬁcally of anaphylaxis.112 Additionally,
a double-blind, placebo controlled study on patients with food
challenge-conﬁrmed FA to milk, egg, peanut, cashew, and/or
hazelnut indicated that clinicians should not use the eliciting dose
obtained from a graded food challenge.109 This is because eliciting
dose only contributes to reaction severity. A successful diagnostic
allergy work-up is required to tailor medical treatments to indi-
vidual characteristics of each FA patient.113 Extensive immune and
allergy workups are becoming more and more important for many
diseases.114 For FA diagnosis, a comprehensive toolbox for improved
documentation and decision-making using oral food challenges has
been provided.115 With these tools, we hope to reduce the inﬂuence
of subjective judgment of supervising physicians.115
Innovative solutions: allergen exposure chambers
Allergen exposure chambers have proven to be valuable tools for
diagnosis and determining safety and efﬁcacy of new
therapeutics.116e119 This tool can help to develop further evidence
for allergen immunotherapy as well as biological therapies, which
can potentially control allergic diseases.120e122 Allergen exposure
chambers also provide a new setting which has generated evidence
that in patients with AD with grass pollen sensitization is linked to
a worsening of cutaneous symptoms.123 Although facilities have
been reported as technically validated, various technical setups and
speciﬁcations are found in allergen exposure chamber facilities.124
Furthermore, several unmet needs require attention and evalua-
tion before allergen exposure chambers can be used in allergen
immunotherapy clinical trials.125 Thus, it is necessary to stan-
dardize allergen exposure chambers, and harmonize protocols for
clinical and immunological research in order to improve data
quality and facilitate better application of allergen exposure
chambers. Currently, the EAACI position paper harmonizes current
concepts of allergen exposure chambers with regard to standardi-
zation of the challenge procedure and assessments, pediatric is-
sues, and regulatory issues.126 These relevant unmet needs and
issues may be addressed before determining safety and efﬁcacy of
new therapeutics.126
Animal models in AD and FA
Animal models of human diseases are commonly utilized for the
development of new drugs and the analysis of pathogenic research.
Current animal research targets speciﬁc immune mechanisms
involved in human atopic and allergic diseases.127 In AD, AIT has
been recently reported in a randomized controlled trial and meta-
analysis, especially in patients sensitized to the house dust mite
antigen.128e130 However, there is still controversy about the role of
AIT as a therapeutic intervention in AD. Several reasons exist for
this, such as there is no relevant mouse model to investigate the
mechanism and validate AIT in AD and primary end points were not
achieved in several proof of concept clinical trials in AD. Shin et al.
established an AIT model of AD using Dermatophagoides farinae
treated NC/Nga mice and demonstrated clinical and histological
improvement.131 They found that induction of Tregs and IL-10-
producing NK cells is a possible source of IL-10 and this model
may be a useful tool to analyze the efﬁcacy of AIT modalities for the
treatment of AD.131
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In a recent study a method to directly assess in vivo the
epidermal barrier function by electrical impedance (EI) spectros-
copy was ﬁrst time demonstrated in mice demonstrating a reliable
diagnostic tool to detect skin barrier defects.132 Mice epidermal
barrier was damaged by epicutaneous application of proteases and
cholera toxin and by tape stripping. EI and transepidermal water
loss (TEWL) were measured before and after the application. A few
hours after papain application, a dose-dependent reduction of EI
was detected, reﬂecting the decreased barrier function. 24 and 48 h
after the treatment, EI starts to increase to background levels,
indicating tissue healing and restoration of skin barrier.132 Barrier
disruption was conﬁrmed by histological analysis showing an
impaired stratum corneum and higher cellular inﬁltration after
papain application.132 In addition, immunoﬂuorescence staining
and RT-PCR showed downregulation of molecules involved in the
barrier function, such as ﬁlaggrin, occludin and claudin-1 and
mRNA levels of ﬁlaggrin, loricrin, and involucrin. Comparable re-
sults were observed after tape stripping and cholera toxin
treatment.
In FA, various animals have been used for studying the mecha-
nisms of FA.133 Adverse reactions to food also occur in companion
animals and comparison between humans and animal models may
lead to improved recommendations for the prevention and treat-
ment of FA.134 Similar to humans, companion animals may spon-
taneously develop skin, respiratory, and gastrointestinal tract
symptoms.135 However, there is no clear evidence between adverse
food reactions and respiratory symptoms in companion animals.136
For example, in dogs, adverse food reactions may manifest as
cutaneous symptoms, which frequently are indistinguishable from
AD due to environmental allergens.137 In addition, little is known
about the mechanisms of FA reactions in companion animals. In
dogs, an allergen speciﬁc IgE response and CD8þ T cell phenotype
have been studied for the mechanism of FA.138 Based on the current
knowledge and the EAACI position paper, comparative studies of
companion animals and humans suffering from FA may serve to ﬁll
knowledge gaps in this area.136
Mechanisms and pathophysiology of food allergy
In food allergic patients, exposure to food antigens elicits a type
1 hypersensitivity reaction, which induces anaphylaxis. Atopic
diseases are signiﬁcantly associated with food induced anaphylaxis
both in children and adults, but not with anaphylaxis induced by
drug and venom.139 Oral tolerance is the mechanism by which we
maintain a normal physiological response to food antigens, and the
breakdown of oral tolerance is likely to be linked to sensitization to
food allergens. In humans, early skin barrier disruption due to
inﬂammation is associated with an increased risk of FA.140,141
Environmental exposure to food allergens can occur in house and
bed dust after hen's egg consumption.142 Importantly, oral expo-
sure is also one of the routs for sensitization to allergens.143
Recently, Lexmond et al. demonstrated that a loss of function mu-
tation in the Wiskott-Aldrich syndrome (Was) protein lead to an
increased risk of FA.144 They showed that Was/ mice became
sensitized to OVA upon oral administration in the absence of
adjuvant, resulting in the development of IgE-mediated mast cell
responses and FA. Studies from Was/ mice will provide new in-
sights into the pathophysiology of FA in humans. Vitamin D plays a
critical role in the stabilization of mast cells, which automatically
activate in vitamin D deﬁcient conditions.145 However, there is no
evidence that vitamin D insufﬁciency during the ﬁrst 6 month of
infancy is a risk factor for IgE-mediated FA at 1 year of age.146 Other
factors such as genes (e.g., ﬁlaggrin gene mutation) and micro-
biome are also related to FA.147 One potentially important gene is
the signal transducer and activator of transcription 6 (STAT6),
which stimulates Th2 differentiation. In this context, van Ginkel
et al. identiﬁed for the ﬁrst time that risk variants increase STAT6
expression and STAT6 variants may be involved in the pathogenesis
of FA.148 Multiple studies have provided evidence that FA is deter-
mined in part, by the microbiome.141 Prior studies investigated the
association in infants of the intestinal microbiome and allergic
disease in humans.37 In a prospective microbiome-wide association
study, bacterial genera present in the infant intestinal microbiome
were inversely associated with the development of food sensiti-
zation at the age of 3 years.149 Recently, epigenetic mechanisms
have been suggested to play a role in FA.147,150 For example, dif-
ferences in epigenetic changes in DNAmethylation of the promoter
region of Th1 and Th2 cytokine genes and Treg play a role in chil-
dren with IgE-mediated cow's milk allergy.151,152 Identiﬁcation of
speciﬁc miRNAs and their targets may help to understand the
mechanism of FA. miR193a-5p is the most downregulated miRNA
in children with cow's milk allergy and the inhibition of miR193a-5
resulted in elevation of protein level of IL-4.153
Although allergy to cow's milk and hen egg is more common
among younger children, the mechanisms of the natural develop-
ment of tolerance remains poorly understood.154 They are typically
sensitized with cow's milk proteins, such as casein and lactoglob-
ulin.155 IgG4 antibodies have been proposed to be a good indicator
of the clinical efﬁcacy of allergy treatments.156 Recent analysis of
IgG4 epitope binding in patients with cow's milk allergy in children
revealed that the number of peptides bound by IgG4 antibodies and
intensity of binding decreased when patients became tolerant,
suggesting that these antibodies are important in tolerance acqui-
sition.157 Cow's milk formulas differ with regard to the degree of
hydrolysis of the mild protein. In this context, several mild hydro-
lyzed cow's formulas are available and useful for the avoidance of
cow's milk allergy in children due to different properties with re-
gard to allergenic activity, IgE reactivity, T-cell proliferation, and
cytokine secretion.158 Tolerance to baked egg and cow's milk is
related to conformational changes induced by heating.159 However,
reaction threshold data from 352 children, who underwent food
challenges to fresh or extensively heated hen's egg and cow's milk
found no signiﬁcant shift in dose-distribution curves by baking
process.160
Almost 70% of patients with birch pollen sensitivity have IgE-
mediated reactions to plant foods such as hazelnut, apple, stone
fruits, kiwi, and carrot, which typically cause oral allergy syn-
drome.161,162 These food allergies are caused by a sensitization to
Bet v 1 and subsequent IgE and T-cell cross-reactivity to food al-
lergens.161 Dau c 1 has been suggested as a major allergy in carrot
allergic patients.163 Dau c 1-speciﬁc T cell lines established from
patients with birch pollen and carrot allergy indicated that T cell
response to Dau c1 occurs independently of Bet v 1, suggesting that
in addition to cross-reactivity with the major pollen allergens, Dau
c 1 itself shows sensitization activity.164
Novel strategies for the treatment and management of food
allergy
The current treatment approach of FA is strict avoidance of the
offending food or foods and the use of rescue medication in the
event of an allergic reaction.165 Therefore, a signiﬁcant amount of
research has been conducted on food AIT including OIT, sublingual
immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT).
The aim of food AIT is to achieve clinical desensitization, sustained
unresponsiveness, and oral tolerance, which are essential for
emerging therapies for FA.166 The EAACI Task Force on Allergen
Immunotherapy for IgE-mediated FA provided evidence-based
recommendations for active treatment with AIT.167 Food AIT has
shown the greatest promise for children 4e5 years of age with
K. Sugita, C.A. Akdis / Allergology International xxx (xxxx) xxx 7
Please cite this article as: Sugita K, Akdis CA, Recent developments and advances in atopic dermatitis and food allergy, Allergology International,
https://doi.org/10.1016/j.alit.2019.08.013
symptoms suggestive of persistent IgE-mediated FA to cow's milk,
hen's egg, or peanut.167 In addition to the improvement of symp-
toms, quality of life of patients with FA improves during OIT for
allergy.168 In other words, a greater understanding of psychological
and physical outcomes contribute to prevention and intervention
in FA.169 Current studies have enrolled patients with heterogeneous
clinical symptoms.170 Most children with milk and egg allergy
develop tolerance spontaneously. Although OIT has been shown to
be more efﬁcient than SLIT, OIT has demonstrated a higher fre-
quency of adverse events.167 In clinical settings, increasing doses
during the build-up phase should be performed in food AIT.171
Novel studies have been conducted adding anti-IgE as a biological
to improve food AIT. Addition of anti-IgE therapy reduces the
allergic side effects of food AIT as it was shown for other AITs.172,173
To ensure efﬁcacy and safety of food AIT, patient factors such as age,
co-existence of other allergic diseases, and adherence should be
considered.167,170 Development of education and training of pri-
mary care professionals, diagnosis and stratiﬁcation of patients, and
monitoring of treatment effectiveness are required for AIT.174
New developments in technology and the combination of two
therapeutic strategies offers opportunities to improve treatment
with AIT.175 Encapsulation of allergens or DNA vaccines into
nanoparticles may provide advantages compared to conventional
AIT.176,177 Srivastava et al., investigated the efﬁcacy and safety of
peanut OIT using CpG-coated nanoparticles containing a peanut
extract in a mouse model of peanut allergy.178 They found that mice
treated with the nanoparticles were signiﬁcantly protected from
anaphylaxis.178 For the improvement of SLIT treatment, combina-
tion therapy with systemic administration of IL-2/anti-IL-2 com-
plexes suppresses experimental FA in mice. Combination therapy
may represent a promising strategy for the treatment and man-
agement of FA.179 Another recent focus has turned to primary
prevention of FA.180 Early peanut introduction is one way to pre-
vention, but early peanut recommendations differ among countries
with formal guidelines.181 Furthermore, there is evidence sup-
porting that early egg introduction can decrease the risk of devel-
oping egg allergy.182
Conclusion
In conclusion, we have reviewed the recent developments on
AD and FA. An important feature of these recent developments is
that the era of precision medicine brings novel strategies in the
management and treatment of AD and FA. Development of a pre-
vention strategy, early interventions and psychological disturbance
are important aspects of patient care. The emergence of novel
diagnostic tools, innovative solutions, and biomarkers as well as
novel mechanisms of AD and FA can be used to accelerate the
development of novel drugs and targeted therapies. Identifying
treatment effects and looking at candidate biomarkers in both an-
imal models and humans will provide evidence to promote the
ability to practice personalized treatment.
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